Dataset Information

Metachronous breast cancer in a male with previous history of liposarcoma: A case report from Syria.

ABSTRACT:

Introduction

Multiple primary cancers (MPC) are defined as the occurrence of two or more non-related cancers. The acquiring of male breast cancer (MBC) as secondary cancer in a sequence of MPC is extremely rare. Only one case of breast cancer following liposarcoma (LP) was previously reported in a female patient. We report the first case of MBC following LP.

Case presentation

A non-smoker male patient with a history of a well-differentiated liposarcoma was treated surgically and with radiotherapy 14 years ago with no signs of recurrence. The patient presented with a left breast mass; The excisional biopsy showed poorly differentiated grade III invasive ductal carcinoma. The patient underwent a mastectomy with axillary node resection and the final diagnosis was invasive ductal carcinoma stage IIA [T:2, N:0, M:0]. The tumor markers reported; Positive Estrogen Receptor (ER+), negative Progesterone Receptor (PR-), and negative Human Epidermal Receptor (HER-). He received eight sessions of chemotherapy with Docetaxel and 16 fractions of radiotherapy. The follow-up showed no signs of recurrence.

Discussion

Despite the rarity of diagnosis MBC as a second primary. Studies have found a relation between different types of breast cancer in male patients, and further, a relation was also found between MBC and lymphoma. While no studies that link MBC and LP were previously reported.

Conclusion

We found that acquiring a treated LP would not affect the MBC prognosis or its response to treatment, yet further studies are needed to confirm this outcome.

SUBMITTER: Tarrab R

PROVIDER: S-EPMC8654778 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Introduction and importance Double gallbladders are a rare anomaly occur in biliary system during the fetal life. In most cases they are asymptomatic, but in few patients, they can progress as a sever disease. Preoperative diagnose is essential in order to prevent surgery complexities and prevent the undesired complications. Case presentation We described a typical case of symptomatic duplicate gallbladder in a 42-year-old man who suffered from chronic abdominal symptoms without determining the cause. The accessory gallbladder was discovered by imagining screening tools which included ultrasound and magnetic resonance cholangiopancreatography and was treated successfully with laparoscopic cholecystectomy, where both gallbladders were removed without any complications. Clinical discussion Double gallbladder are rare abnormality occur in fetal life during the fifth and sixth weeks of pregnancy. In most cases they show zero symptoms and can be easily wandered off during typical preoperative screening. Therefor many diagnostic tools were developed to investigate this anomaly in order to prevent its unwanted outcomes and to help the surgeon in deciding the best surgical approach for each presenting case. Conclusion In order to prevent complications during surgery, it is vital that we investigate the presence of a double gallbladder in a surgical patient before the procedure. Highlights • The presence or absence of sickness in accessory gallbladder depends on the presence or absence of complications which are caused by the same Pathogenic factors that are indicted in complicated mono gall bladder.• As ultrasounds can be limited in distinguishing bilobed gallbladder and real duplication, a following MRI should be performed for better investigating and evaluation.• In accidental cases, both gallbladders should be considered if the surgical approach was approved.• In H-type double gallbladder intervention there is a high potential to damage the biliary ducts and arteria hepatica.

Project description:Male breast cancer is a rare event, accounting for approximately 1% of all breast carcinomas. Although men with breast cancer had poorer survival when compared with women, data on prognosis principally derive from retrospective studies and from extrapolation of female breast cancer series. We reported the case of a very long survival patient.A caucasian 42-year-old man underwent radical mastectomy with axillary dissection for breast cancer in 1993. Pathologic stage was pT4pN0M0 infiltrating ductal carcinoma of right breast without lymph nodes metastases. Biological characterization was not available. He received adjuvant treatment with chemotherapy, six cycles of cyclophosphamide, methotrexate and fluorouracil, then endocrine therapy with tamoxifen for 5 years and complementary radiotherapy. Then he began clinical-instrumental follow up. In May 1996, a computed tomography scan showed multiple lung metastases. Hereafter he received several oncologic treatment including seven chemotherapy and five endocrine therapy lines with two re-challenge of endocrine therapy. In October 2007 further lung progression was showed and a biopsy was performed to characterize the disease. Histological examination confirmed breast cancer metastases, immunohistochemistry showed positive staining for estrogen receptor, negative for progesterone receptor and human epithelial growth factor receptor 2, proliferative index was 21%. In April 2013, bone disease progression was evident and he received radiant treatment to sacral spine. In May 2014 an off-label treatment with exemestane and everolimus combination was approved by Ethics Committee of the Marche Region. The patient received treatment for 3 months with evident clinical benefit to subcutaneous lesions of the chest wall that were not visible nor palpable on physical examination after 1 month of treatment.That is the case of long survival male breast cancer patient with luminal B subtype and no BRCA mutations. He achieved higher progression free survival with endocrine therapy creating the rationale for last line treatment with everolimus and exemestane combination. Attending conclusive results from ongoing studies, everolimus and exemestane should not be used routinely in male metastatic breast cancer patients, but taking into account for selected cases. At the best of our knowledge, this is the first case of male beast cancer treated with exemestane and everolimus combination.